Osteoporosis is so difficult to detect in early stage it’s called the “silent disease.” What if artificial intelligence could help predict a patient’s chances of having the bone-loss disease before ever stepping into a doctor’s office?
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15 | Psychedelic Invest
SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing
July 20, 2024